A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 07 2023
25 07 2023
Historique:
received:
03
02
2023
accepted:
14
06
2023
medline:
27
7
2023
pubmed:
26
7
2023
entrez:
25
7
2023
Statut:
epublish
Résumé
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.
Identifiants
pubmed: 37491478
doi: 10.1038/s41598-023-36990-9
pii: 10.1038/s41598-023-36990-9
pmc: PMC10368624
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11327Subventions
Organisme : Cancer Research UK
ID : 28990
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 30195
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Investigateurs
Emma Kinloch
(E)
Emily Lam
(E)
Gillian Murphy
(G)
Malcolm Rhodes
(M)
Kate Robinson
(K)
Informations de copyright
© 2023. The Author(s).
Références
Lancet Oncol. 2022 Jul;23(7):865-875
pubmed: 35660139
Viruses. 2022 May 04;14(5):
pubmed: 35632703
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Ann Rheum Dis. 2022 Dec;81(12):1742-1749
pubmed: 35944947
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nat Cancer. 2021 Dec;2(12):1321-1337
pubmed: 35121900
J Thorac Oncol. 2022 Feb;17(2):239-251
pubmed: 34798306
JAMA Netw Open. 2023 Apr 3;6(4):e239694
pubmed: 37093599
Lancet Oncol. 2022 Jun;23(6):748-757
pubmed: 35617989
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Lancet Haematol. 2021 Aug;8(8):e542-e544
pubmed: 34224667
Cancer Cell. 2022 Apr 11;40(4):343-345
pubmed: 35219358
Nat Rev Clin Oncol. 2020 Jun;17(6):329-331
pubmed: 32296166
Br J Cancer. 2022 Nov;127(10):1827-1836
pubmed: 36224402
Cancer Cell. 2020 Sep 14;38(3):306-307
pubmed: 32730750
BMC Infect Dis. 2022 Jan 31;22(1):107
pubmed: 35100985
Eur J Cancer. 2022 Nov;175:1-10
pubmed: 36084618
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Br J Haematol. 2023 Jun;201(5):813-823
pubmed: 37006158
Eur J Cancer. 2022 Jan;160:243-260
pubmed: 34794855
Cancer Cell. 2022 Jan 10;40(1):3-5
pubmed: 34838186
JAMA Oncol. 2023 Feb 1;9(2):188-196
pubmed: 36547970
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
J Clin Oncol. 2022 Jan 1;40(1):12-23
pubmed: 34752147
BMC Infect Dis. 2022 Oct 27;22(1):802
pubmed: 36303111
Lancet Oncol. 2022 Feb;23(2):193-195
pubmed: 34953523
BMC Cancer. 2022 Aug 4;22(1):850
pubmed: 35927617